Does the routine use of global coronary heart disease risk scores translate into clinical benefits or harms? A systematic review of the literature Public Deposited
Downloadable ContentDownload PDF
- Other Affiliation: Division of Cardiology, University of Vermont, Burlington, VT, USA
- Affiliation: School of Medicine, Department of Medicine, Division of General Medicine and Clinical Epidemiology
- Abstract Background Guidelines now recommend routine assessment of global coronary heart disease (CHD) risk scores. We performed a systematic review to assess whether global CHD risk scores result in clinical benefits or harms. Methods We searched MEDLINE (1966 through June 13, 2007) for articles relevant to our review. Using predefined inclusion and exclusion criteria, we included studies of any design that provided physicians with global risk scores or allowed them to calculate scores themselves, and then measured clinical benefits and/or harms. Two reviewers reviewed potentially relevant studies for inclusion and resolved disagreement by consensus. Data from each article was then abstracted into an evidence table by one reviewer and the quality of evidence was assessed independently by two reviewers. Results 11 studies met criteria for inclusion in our review. Six studies addressed clinical benefits and 5 addressed clinical harms. Six studies were rated as "fair" quality and the others were deemed "methodologically limited". Two fair quality studies showed that physician knowledge of global CHD risk is associated with increased prescription of cardiovascular drugs in high risk (but not all) patients. Two additional fair quality studies showed no effect on their primary outcomes, but one was underpowered and the other focused on prescribing of lifestyle changes, rather than drugs whose prescribing might be expected to be targeted by risk level. One of these aforementioned studies showed improved blood pressure in high-risk patients, but no improvement in the proportion of patients at high risk, perhaps due to the high proportion of participants with baseline risks significantly exceeding the risk threshold. Two fair quality studies found no evidence of harm from patient knowledge of global risk scores when they were accompanied by counseling, and optional or scheduled follow-up. Other studies were too methodologically limited to draw conclusions. Conclusion Our review provides preliminary evidence that physicians' knowledge of global CHD risk scores may translate into modestly increased prescribing of cardiovascular drugs and modest short-term reductions in CHD risk factors without clinical harm. Whether these results are replicable, and translate across other practice settings or into improved long-term CHD outcomes remains to be seen.
- Date of publication
- March 20, 2008
- Resource type
- Rights statement
- In Copyright
- Rights holder
- Stacey L Sheridan et al.; licensee BioMed Central Ltd.
- Journal title
- BMC Health Services Research
- Journal volume
- Journal issue
- Page start
- Is the article or chapter peer-reviewed?
- Bibliographic citation
- BMC Health Services Research. 2008 Mar 20;8(1):60
- Open Access
- BioMed Central Ltd
This work has no parents.
|Summary of overall study quality rating, table summarizing study quality ratings||2019-05-06||Public||
|Characteristics of studies addressing the clinical benefits of global risk scores, table summarizing study characteristics||2019-05-06||Public||
|Literature search strategy, literature search strategy||2019-05-06||Public||
|Characteristics of studies addressing the harms of global risk scores, table summarizing study characteristics||2019-05-06||Public||